New vaccine boosts CAR-T power against bone marrow cancer
NCT ID NCT07377435
First seen Feb 01, 2026
Summary
This early-stage trial tests whether adding a personalized cancer vaccine (made from a patient's own immune cells and tumor cells) to standard CAR-T cell therapy can safely improve outcomes for people with multiple myeloma that has returned or stopped responding to treatment. About 25 adults will receive the vaccine plus a growth factor alongside their CAR-T therapy. The study focuses on safety first, but also looks at how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized cancer vaccine (DC/MM fusion vaccine) plus growth factor (GM-CSF)
What this could lead to
If it works, this combination could improve the effectiveness of CAR-T therapy and help more people with multiple myeloma achieve long-term remission.
What could go wrong
This is a very early Phase 1 trial with only 25 people, so safety and effectiveness are still unknown. There are risks of serious side effects like cytokine release syndrome and nerve problems.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.